Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Open accessThe DOI matches its Crossref record.
Abstract
Purpose Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. Experimental Design 17-DMAG was administered as a 1- to 2-h infusion twice weekly in 4-week cycles. An accelerated titration design was followed until toxicity was observed, at which point standard dose escalation proceeded. MTD was defined as the dose at which no more than one of six patients experienced a dose-limiting toxicity (DLT). Pharmacokinetics were assessed, and Hsp70 mRNA, whose gene product is a chaperone previously shown to be upregulated following inhibition of Hsp90, was measured in peripheral blood mononuclear cells (PBMCs). Results A total of 31 patients received 92 courses of treatment. The MTD was 21 mg/m2/d; 20 patients were enrolled at this dose level. Nine patients had stable disease for a median of 4 (range 2-22) months. Both Cmax and AUC increased proportionally with dose. The most common toxicities were grade 1 or 2 fatigue, anorexia, nausea, blurred vision, and musculoskeletal pain. DLTs were peripheral neuropathy and renal dysfunction. Expression of Hsp70 mRNA in PBMCs was highly variable. Conclusion Twice-weekly i.v. infusion of 17-DMAG is well tolerated, and combination phase I studies are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Self-citationTargeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Chatterjee, S., & Burns, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091978 · Cited by 501
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.008 · Cited by 456
Targeting heat shock proteins in cancer
Jego, G., Hazoumé, A., Seigneuric, R., & Garrido, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.10.014 · Cited by 452
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Metadata
- Authors
- Kummar, S., Gutierrez, M. E., Gardner, E. R., Chen, X., Figg, W. D., Zajac-Kaye, M., Chen, M., Steinberg, S. M., Muir, C. A., Yancey, M. A., Horneffer, Y. R., Juwara, L., Melillo, G., Ivy, S. P., Merino, M., Neckers, L., Steeg, P. S., Conley, B. A., Giaccone, G., Doroshow, J. H., & Murgo, A. J.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 46
- Issue
- 2
- Pages
- 340-347
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2108502796
- Cited by
- 122
- References
- 0
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. https://app.cochat.ai/papers/10.1016/j.ejca.2009.10.026
- The paper
- Kummar, S., Gutierrez, M. E., Gardner, E. R., Chen, X., Figg, W. D., Zajac-Kaye, M., Chen, M., Steinberg, S. M., Muir, C. A., Yancey, M. A., Horneffer, Y. R., Juwara, L., Melillo, G., Ivy, S. P., Merino, M., Neckers, L., Steeg, P. S., Conley, B. A., Giaccone, G., . . . Murgo, A. J. (2010). Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2009.10.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.